A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma

Ophthalmology

Volumn 105, Issue 11, 1998, Pages 2035-2045

  Kroll, Stew ^a   Char, Devron H ^a   Quivey, Jeanne ^a   Castro, Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; FEMALE; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; UNITED STATES; UVEA MELANOMA;

EID: 0032471480     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)91121-6     Document Type: Article

References (36)

1. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A metaanalysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110:245-50.
2. 125I brachytherapy versus helium ion irradiation. Ophthalmology 1989;96:1708-15.
3. Char DH, Castro JR, Kroll SM, et al. Five-year follow-up of helium ion therapy for uveal melanoma. Arch Ophthalmol 1990;108:209-14.
4. Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547-54.
5. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-77.
6. Augsburger JJ, Gamel JW, Sardi VF, et al. Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body. Arch Ophthalmol 1986;104:655-61.
7. Brady LW, Hernandez JC. Brachytherapy of choroidal melanomas. Strahlenther Onkol 1992;168:61-5.
8. Zografos L, Bercher L, Egger E, et al. Le traitement des tumeurs oculaires par faisceau de protons accéléré: 7 ans d'expērience [Engl abstr]. Klin Monatsbl Augenheilkd 1992; 200:431-5.
9. Manschot WA, Lee WR, Strik R. Uveal melanoma: updated considerations on current management modalities. Int Ophthalmol 1995;19:203-9.
10. Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for melanoma. Am J Ophthalmol 1998;125:81-9.
11. Char DH. Clinical ocular oncology, 2nd ed. Philadelphia, PA: Lippincott-Raven, 1987.
12. Gragoudas ES, Seddon JM, Egan KM, et al. Metastasis from uveal melanoma after proton beam irradiation. Ophthalmology 1988;95:992-8.
13. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh) 1982;60:161-82.
14. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983;101: 1894-9.
15. Coleman K, Baak JPA, Van Diest P, et al. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 1993;77:688-92.
16. DePotter P, Shields CL, Shields JA, et al. Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival. Br J Ophthalmol 1994;78:109-14.
17. Gamel JW, McLean IW, Greenberg RA. Interval-by-interval Cox model analysis of 3680 cases of intraocular melanoma shows a decline in the prognostic value of size and cell type over time after tumor excision. Cancer 1988;61:574-9.
18. Callender GR, Wilder HC, Ash JE. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol 1942;25:962-7.
19. Wright CJE. Prognosis in cutaneous and ocular malignant melanoma: a study of 222 cases. J Pathol Bact 1949;61:507-25.
20. Packard RBS. Pattern of mortality in choroidal malignant melanoma. Br J Ophthalmol 1980;64:565-75.
21. Hagler WS, Jarrett WH, II, Killian JH. The use of the 32P test in the management of malignant melanoma of the choroid: a five-year follow-up study. Trans Am Acad Ophthalmol Otolaryngol 1977;83:49-60.
22. Char DH, Stone RD, Irvine AR, et al. Diagnostic modalities in choroidal melanoma. Am J Ophthalmol 1980;89:223-30.
23. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society B 1972;34:187-220.
24. Anderson PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag, 1993 (Springer series in statistics).
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. JASA 1958;53:457-81, 562-3.
26. Keiding N, Vaeth M. Calculating expected mortality. Stat Med 1986;5:327-34.
27. Berry G. The analysis of mortality by the subject-years method. Biometrics 1983;39:173-84.
28. U.S. Decennial Life Tables for 1979-81, v. 1, no. 3. Hyattsville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Statistics; Washington, DC: for sale by the Supt. of Docs. U.S. G.P.O. 1985-(DH'HS publication).
29. Crowder M. Identifiability crises in competing risks. International Statistical Review 1994;62:379-91.
30. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al. The analysis of failure times in the presence of competing risks. Biometrics 1972;34:541-54.
31. Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies. Biometrics 1990;46:813-26.
32. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology, data. Journal of the American Statistical Association 1993;88:400-9.
33. Geotghebeur E, Ryan L. A modified log rank test for competing risks with missing failure type. Biometrika 1990;77:207-11.
34. Cheuvart B, Ryan L. Adjusting for age-related competing mortality in long-term cancer clinical trials. Stat Med 1991; 10:65-77.
35. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. Control Clin Trials 1993;14:362-91.
36. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996;114:107-8.